Evidence map›Paper›PMID 35398318›Full record

ArticleChest2022

No VTE Recurrence After 1-Year Follow-Up of Hospitalized Patients With COVID-19 and a VTE Event: A Prospective Study.

Maxime Delrue, Alain Stépanian, Sebastian Voicu, Kladoum Nassarmadji, Damien Sène, Philippe Bonnin, Jean-Philippe Kevorkian, Pierre-Olivier Sellier, Jean-Michel Molina, Marie Neuwirth and 5 more

Abstract read
In one paragraph

Article in Chest, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. COVID-19 and Recurrent Venous Thromboembolism (CORE-VTE).The Canadian journal of hospital pharmacy · 2025
    Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Maxime DelrueHematology Laboratory & Thrombosis unit, Université Paris Cité, Hospital group Lariboisière-Fernand Widal, APHP, Paris, France; EA 3518, Université Paris Cité, Paris, France.
Alain StépanianHematology Laboratory & Thrombosis unit, Université Paris Cité, Hospital group Lariboisière-Fernand Widal, APHP, Paris, France; EA 3518, Université Paris Cité, Paris, France.
Sebastian VoicuDepartment of Medical and Toxicological Critical Care, Université Paris Cité, Hospital group Lariboisière-Fernand Widal, APHP, Paris, France; INSERM UMRS-1144, Université Paris Cité, Paris, France.
Kladoum NassarmadjiDepartment of Internal Medicine, Université Paris Cité, Hospital group Lariboisière-Fernand Widal, APHP, Paris, France.
Damien SèneDepartment of Internal Medicine, Université Paris Cité, Hospital group Lariboisière-Fernand Widal, APHP, Paris, France.
Philippe BonninLaboratory of Clinical Physiology, Université Paris Cité, Hospital group Lariboisière-Fernand Widal, APHP, Paris, France; INSERM UMRS-1148, Université Paris Cité, Paris, France.
Jean-Philippe KevorkianDepartment of Diabetology-Endocrinology, Université Paris Cité, Hospital group Lariboisière-Fernand Widal, APHP, Paris, France.
Pierre-Olivier SellierDepartment of infectious disease, Université Paris Cité, Hospital group Lariboisière-Fernand Widal, APHP, Paris, France.
Jean-Michel MolinaDepartment of infectious disease, Université Paris Cité, Hospital group Lariboisière-Fernand Widal, APHP, Paris, France.
Marie NeuwirthHematology Laboratory & Thrombosis unit, Université Paris Cité, Hospital group Lariboisière-Fernand Widal, APHP, Paris, France; INSERM UMRS-1140, Université Paris Cité, Paris, France.
Dominique VodovarINSERM UMRS-1144, Université Paris Cité, Paris, France; Paris Poison Control Center, Université Paris Cité, Hospital group Lariboisière-Fernand Widal, APHP, Paris, France.
Stéphane MoulyINSERM UMRS-1144, Université Paris Cité, Paris, France; Department of Internal Medicine, Université Paris Cité, Hospital group Lariboisière-Fernand Widal, APHP, Paris, France.
Alexandre MebazaaDepartment of Anesthesiology and Critical Care, Université Paris Cité, Hospital group Lariboisière-Fernand Widal, APHP, Paris, France; INSERM UMRS-942, Université Paris Cité, Paris, France.
Bruno MégarbaneDepartment of Medical and Toxicological Critical Care, Université Paris Cité, Hospital group Lariboisière-Fernand Widal, APHP, Paris, France; INSERM UMRS-1144, Université Paris Cité, Paris, France.
Virginie SiguretHematology Laboratory & Thrombosis unit, Université Paris Cité, Hospital group Lariboisière-Fernand Widal, APHP, Paris, France; INSERM UMRS-1140, Université Paris Cité, Paris, France. Electronic address: virginie.siguret@aphp.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Venous ThromboembolismVenous ThrombosisAnticoagulantsFollow-Up StudiesHumansProspective StudiesRecurrenceRisk FactorsAnticoagulants

Identifiers

PMID35398318
PMCPMC8986540

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.